Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 13/20 | 0.40 |
| ▸ | HTR2C | P28335 | 13/20 | 0.40 |
| ▸ | HTR2B | P41595 | 13/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426359 | 0.90 | PNMT (0.37) | MAPTHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL2202293 | 0.81 | SOS1 (0.44) | MAPTSOS1 | |
| SCHEMBL12426340 | 0.81 | ACHE (0.43) | MAPTSOS1 | |
| SCHEMBL2199388 | 0.75 | PRKD3 (0.34) | HTR2BPRKD3TGFBR1PRKD1PRKD2 | |
| SCHEMBL12426171 | 0.74 | TGFBR1 (0.40) | MAPTHTR2AHTR2CHTR2BPRKD3 | |
| SCHEMBL2203166 | 0.73 | MAOA (0.34) | HTR2BPRKD3TGFBR1PRKD1PRKD2 | |
| SCHEMBL2200247 | 0.73 | PRKD3 (0.33) | HTR2BPRKD3TGFBR1PRKD1PRKD2 | |
| SCHEMBL2201678 | 0.72 | IDH1 (0.34) | HTR2BPRKD3TGFBR1PRKD1PRKD2 | |
| SCHEMBL12426424 | 0.72 | IDH1 (0.34) | HTR2BPRKD3TGFBR1PRKD1PRKD2 | |
| SCHEMBL12426347 | 0.71 | ACHE (0.44) | MAPTSOS1PRKD3TGFBR1PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | MAPT 3915/4885HTR2A 4027/4885HTR2C 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.